Letters to the Editor

Risks of and Indications for Mifepristone for Medication Abortion

 

Am Fam Physician. 2022 Jan ;105(1):5.

Original Article: Mifepristone and Misoprostol for Early Pregnancy Loss and Medication Abortion

Issue Date: April 15, 2021

See additional reader comments at: https://www.aafp.org/afp/2021/0415/p473.html

To the Editor: We believe more information should be offered about the risks and indications for mifepristone (Mifeprex) for medication abortion. Tables 1 and 2 in the article emphasize the need for a careful history, physical examination, and important laboratory studies to determine eligibility. However, the authors do not emphasize in-person visits, stating, “Telehealth has been shown to be a safe and effective model for providing medication abortion....” This statement oversimplifies the referenced study,1 which says that “...each participant had ... pre-treatment laboratory tests and ultrasound....” The American College of Obstetricians and Gynecologists reports that approximately one-half of women inaccurately recall the date of their most recent menstrual period; therefore, the estimated gestational age in the first trimester is adjusted in 40% of pregnancies after ultrasonography.2 Without ultrasound visualization to determine an intrauterine pregnancy, it is difficult to diagnose or rule out an early ectopic pregnancy. Telehealth evaluation should not replace an adequate physical examination with vital signs, a speculum, bimanual examination, ultrasonography (for location, dating, and viability), and appropriate laboratory studies, including beta human chorionic gonadotropin, hemoglobin, and Rh status.

The overall complication rate of medication abortion after an appropriate in-person evaluation is 5.2%, based on a large study,3 and the risks of adverse events increase with advancing gestational age. These risks and concerns for diversion and misuse were why the U.S. Food and Drug Administration (FDA) implemented an in-person dispensing requirement. Of the 2,660 unique U.S.-only codable adverse event reports submitted for mifepristone between 2000 and 2016, 73% were classified as severe, 20% were life-threatening, and 0.75% resulted in death. Morbidity was primarily attributed to retained products of conception and hemorrhage, for which women with a gestational age greater than 49 days are at the highest risk. There were 1,639 bleeding events, including 466 life-threatening events, 642 severe events, and 106 moderate events; an additional 424 reports of bleeding were uncodable because of insufficient information. A total of 75 patients had ectopic pregnancies, with 25 presenting with ruptured ectopic pregnancies.4 We would encourage a more detailed review of the risks of mifepristone. Physicians must anticipate and be prepared to manage complications and adverse events that patients experience with mifepristone, especially if there are increasing numbers of medication abortions without an office visit, ultrasonography, and appropriate ancillary studies.

Author disclosure: Dr. Poehailos reports being employed by ThriVe Central VA Women's Healthcare, a nonprofit pregnancy medical clinic, from January 2018 to April 2021. She also serves on the Board of Directors for the National Institute of Family and Life Advocates and the Abortion Pill Rescue Network Medical Advisory Board of Heartbeat International. Dr. Gilbert has no relevant financial relationships.

References

show all references

1. Raymond E, Chong E, Winikoff B, et al. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States. Contraception. 2019;100(3):173–177....

2. The American College of Obstetricians and Gynecologists. ACOG Committee Opinion no. 700. Methods for estimating the due date. May 2017. Accessed July 7, 2021. https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2017/05/methods-for-estimating-the-due-date

3. Upadhyay UD, Desai S, Zlidar V, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol. 2015;125(1):175–183.

4. Aultman KA, Cirucci CA, Harrison DJ, et al. Deaths and severe adverse events after the use of mifepristone as an abortifacient from September 2000 to February 2019. Issues Law Med. 2021;36(1):3–26.

In Reply: Several important studies have been published on this topic recently. We appreciate the opportunity to share more information on the safety and effectiveness of providing mifepristone without in-person testing or ultrasonography. In a cohort study of 54,142 women in Great Britain, the rate of serious adverse events in 18,435 women who had a no-test telemedicine abortion between April and June 2020 (0.04%) was no different than in patients who received traditional in-person care (P = .56).1 In another study, family physicians in the United States successfully provided medication abortion to more than 500 women using an asynchronous telehealth platform, with 90% meeting criteria for no-test abortion care.2

On April 12, 2021, the FDA announced its intention “...to exercise enforcement discretion with respect to the in-person dispensing requirement of the Mifepristone REMS Program, ...during the COVID-19 public health emergency” as a “...result of a thorough scientific review by experts within FDA's Center for Drug Evaluation and Research (CDER), who evaluated relevant information, including available clinical outcomes data and adverse event reports.”3

Mifepristone is one of the most carefully studied medications that has been brought to market. Although the article by Aultman, et al., describes the breakdown of the types of reported adverse events, it does not include the denominator of mifepristone use since FDA approval in 2000.4 Over the past 20 years, mifepristone has been used for medication abortion by more than 2.75 million people, and there have been only 24 deaths, meaning that the risk of death is less than one in 100,000.4 Similarly, in considering the overall 5.2% complication rate after medication abortion reported by Upadhyay, et al., it is important to note that 94% of the documented complications were minor issues; the rate of major complications was 0.31 per 100 abortions. These rates of complications are far lower than rates associated with term delivery and indicate that mifepristone is safer than over-the-counter acetaminophen, which causes 500 deaths per year in the United States.5,6

Author disclosure: No relevant financial relationships.

References

show all references

1. Aiken ARA, Lohr PA, Lord J, et al. Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. BJOG. February 18, 2021. Accessed July 12, 2021. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.16668...

2. Godfrey EM, Thayer EK, Fiastro AE, et al. Family medicine provision of online medication abortion in three US states during COVID-19. Contraception. 2021;104(1):54–60.

3. U.S. Food and Drug Administration. Questions and answers on Mifeprex. Updated April 13, 2021. Accessed June 25, 2021. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-mifeprex

4. Aultman KA, Cirucci CA, Harrison DJ, et al. Deaths and severe adverse events after the use of mifepristone as an abortifacient from September 2000 to February 2019. Issues Law Med. 2021;36(1):3–26.

5. Raymond EG, Grimes DA. The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol. 2012;119(2 pt 1):215–219.

6. Agrawal S, Khazaeni B. Acetaminophen toxicity. StatPearls. November 20, 2020. Accessed December 14, 2021. https://www.ncbi.nlm.nih.gov/books/NBK441917

Send letters to afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.

This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.

 

 

Copyright © 2022 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

MOST RECENT ISSUE


May 2022

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article